IN2014CN04590A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04590A
IN2014CN04590A IN4590CHN2014A IN2014CN04590A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A IN 4590CHN2014 A IN4590CHN2014 A IN 4590CHN2014A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A
Authority
IN
India
Prior art keywords
nucleic acid
acid strand
nucleotides
nucleotide analogs
transcription product
Prior art date
Application number
Other languages
English (en)
Inventor
Takanori Yokota
Kazutaka Nishina
Satoshi Obika
Hidehiro Mizusawa
Original Assignee
Nat Univ Corp Tokyo Med & Dent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Corp Tokyo Med & Dent filed Critical Nat Univ Corp Tokyo Med & Dent
Publication of IN2014CN04590A publication Critical patent/IN2014CN04590A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
IN4590CHN2014 2011-12-16 2012-12-17 IN2014CN04590A (US06268490-20010731-C00004.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011275488 2011-12-16
PCT/JP2012/083180 WO2013089283A1 (en) 2011-12-16 2012-12-17 Chimeric double-stranded nucleic acid

Publications (1)

Publication Number Publication Date
IN2014CN04590A true IN2014CN04590A (US06268490-20010731-C00004.png) 2015-09-18

Family

ID=47559626

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4590CHN2014 IN2014CN04590A (US06268490-20010731-C00004.png) 2011-12-16 2012-12-17

Country Status (9)

Country Link
US (5) US9816089B2 (US06268490-20010731-C00004.png)
EP (1) EP2791335B1 (US06268490-20010731-C00004.png)
JP (7) JP6112569B2 (US06268490-20010731-C00004.png)
CN (2) CN104126010B (US06268490-20010731-C00004.png)
AU (1) AU2012353330B2 (US06268490-20010731-C00004.png)
CA (2) CA2859581C (US06268490-20010731-C00004.png)
ES (1) ES2707232T3 (US06268490-20010731-C00004.png)
IN (1) IN2014CN04590A (US06268490-20010731-C00004.png)
WO (1) WO2013089283A1 (US06268490-20010731-C00004.png)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
CA2859581C (en) * 2011-12-16 2022-03-22 National University Corporation Tokyo Medical And Dental University Chimeric double-stranded nucleic acid
CN104684893B (zh) 2012-07-13 2016-10-26 日本波涛生命科学公司 不对称辅助基团
EP2961841B1 (en) * 2013-03-01 2020-01-22 National University Corporation Tokyo Medical and Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
JP6300212B2 (ja) * 2013-03-21 2018-03-28 国立大学法人 東京医科歯科大学 二重鎖核酸結合剤、当該結合剤−二重鎖核酸複合体、当該複合体を含有する医薬品組成物、及び、当該複合体の製造方法
AU2014282666A1 (en) * 2013-06-16 2016-01-07 National University Corporation Tokyo Medical And Dental University Double-stranded antisense nucleic acid with exon-skipping effect
WO2015105083A1 (ja) * 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
WO2017053999A1 (en) 2015-09-25 2017-03-30 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP3366773A4 (en) * 2015-10-23 2019-06-12 Rena Therapeutics Inc. NUCLEIC ACID COMPLEX
EP3366774A4 (en) * 2015-10-23 2019-03-27 Rena Therapeutics Inc. NUCLEIC ACID COMPLEX WITH AT LEAST ONE WOOD STRUCTURE
WO2017094745A1 (ja) * 2015-12-01 2017-06-08 国立大学法人大阪大学 核酸を含む経腸投与用組成物
CN108884462B (zh) * 2016-01-26 2022-11-25 日产化学株式会社 单链寡核苷酸
MA45328A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
US11433089B2 (en) 2016-09-23 2022-09-06 National University Corporation Tokyo Medical And Dental University Blood-brain barrier permeable heteroduplex nucleic acid
US11260134B2 (en) 2016-09-29 2022-03-01 National University Corporation Tokyo Medical And Dental University Double-stranded nucleic acid complex having overhang
EP3584319A4 (en) 2017-02-06 2021-04-14 Nissan Chemical Corporation SINGLE-STRAND OLIGONUCLEOTIDE
US11638717B2 (en) 2017-03-29 2023-05-02 Shionogi & Co., Ltd. Complex of nucleic acid medicine and multibranched lipid
CN110520532B (zh) * 2017-03-31 2024-02-13 学校法人爱知医科大学 阻碍硫酸软骨素生物合成的反义核酸
US20200115710A1 (en) * 2017-06-30 2020-04-16 National University Corporation Tokyo Medical And Dental University HETERO DOUBLE-STRANDED antimiR
TW201920671A (zh) * 2017-07-26 2019-06-01 日商日產化學股份有限公司 單股寡核苷酸
JP7360170B2 (ja) 2018-02-28 2023-10-12 国立大学法人 東京医科歯科大学 虚血病変部位特異的な遺伝子治療法
KR20190110043A (ko) * 2018-03-19 2019-09-27 주식회사 케이티 비디오 신호 처리 방법 및 장치
US11851654B2 (en) 2018-03-19 2023-12-26 National University Corporation Tokyo Medical And Dental University Nucleic acid with reduced toxicity
US20210054377A1 (en) 2018-03-20 2021-02-25 Tokyo Institute Of Technology Antisense oligonucleotide reduced in toxicity
EP3770257A4 (en) * 2018-03-22 2022-03-09 National University Corporation Tokyo Medical and Dental University BHS-PASSING LIPID LIGAND OF A HETERONUCLEIC ACID
WO2020150636A1 (en) * 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
CN113677374A (zh) 2019-04-08 2021-11-19 国立大学法人东京医科齿科大学 肌疾病治疗用药物组合物
JPWO2021020412A1 (US06268490-20010731-C00004.png) 2019-07-30 2021-02-04
WO2021070959A1 (ja) 2019-10-11 2021-04-15 国立大学法人東京医科歯科大学 修飾ヘテロ核酸
US20230061751A1 (en) * 2020-01-17 2023-03-02 University Of Massachusetts Universal dynamic pharmacokinetic-modifying anchors
KR20220133925A (ko) 2020-01-31 2022-10-05 가부시키가이샤산와카가쿠켄큐쇼 Atn1의 안티센스 올리고뉴클레오티드
US20230159925A1 (en) 2020-03-04 2023-05-25 Nissan Chemical Corporation Antisense oligonucleotide of calm2
JPWO2021187392A1 (US06268490-20010731-C00004.png) 2020-03-16 2021-09-23
WO2021256297A1 (ja) 2020-06-15 2021-12-23 リードファーマ株式会社 架橋型ヌクレオシドおよびヌクレオチド
US20240002853A1 (en) 2020-11-23 2024-01-04 Alpha Anomeric Sas Nucleic acid duplexes
EP4298251A1 (en) * 2021-02-26 2024-01-03 Northwestern University Cell-free biosensors with dna strand displacement circuits
JPWO2022250050A1 (US06268490-20010731-C00004.png) 2021-05-25 2022-12-01
CA3222167A1 (en) 2021-05-31 2022-12-08 Rena Therapeutics Inc. Ligand-binding nucleic acid complex
WO2023022229A1 (ja) 2021-08-19 2023-02-23 国立大学法人東京医科歯科大学 モルホリノ核酸を含む修飾ヘテロ核酸
WO2023026994A1 (ja) 2021-08-21 2023-03-02 武田薬品工業株式会社 ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
WO2023042876A1 (ja) * 2021-09-15 2023-03-23 国立大学法人東京医科歯科大学 ２'－修飾ヌクレオシドを含むヘテロ核酸
JP7412668B2 (ja) * 2021-12-07 2024-01-15 リードファーマ株式会社 アンチセンスオリゴヌクレオチド複合体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110894A (ja) * 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2002249967A1 (en) 2001-11-12 2003-05-26 Epiclone, Inc. Gene silencing using sense dna and antisense rna hybrid constructs
DE10240417A1 (de) 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
EP1546344A4 (en) * 2002-09-18 2007-10-03 Isis Pharmaceuticals Inc EFFICIENT REDUCTION OF TARGET RNA USING OLIGOMERIC COMPOUNDS WITH SINGLE AND DOUBLE STRAPS
EP1569695B1 (en) 2002-11-13 2013-05-15 Genzyme Corporation Antisense modulation of apolipoprotein b expression
WO2005021570A1 (ja) 2003-08-28 2005-03-10 Gene Design, Inc. Ｎ−０結合性架橋構造型新規人工核酸
AR045937A1 (es) * 2003-09-18 2005-11-16 Lilly Co Eli Modulacion de la expresion del factor de iniciacion eucariotico eif4e
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
US20080199960A1 (en) * 2004-05-13 2008-08-21 Juliano Rudolph L Methods for the Delivery of Oligomeric Compounds
EP1838875A4 (en) * 2004-12-30 2010-08-25 Todd M Hauser COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION USING SELF-PROTECTED OLIGONUCLEOTIDES
EP2023939B1 (en) 2006-05-05 2012-06-27 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of pcsk9
KR20090064378A (ko) * 2006-08-10 2009-06-18 온코세라피 사이언스 가부시키가이샤 유방암 관련 유전자 및 폴리펩티드
WO2008029619A1 (fr) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Oligonucléotide antisens ena ayant une action spécifique de la séquence
AU2007306361A1 (en) 2006-10-09 2008-04-17 Santaris Pharma A/S RNA antagonist compounds for the modulation of PCSK9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US7858592B2 (en) * 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
EP2134736A4 (en) * 2007-03-15 2013-05-29 Jyoti Chattopadhyaya FIVE- AND SIX-PIECE CONFORMATIVELY FIXED 2 ', 4'-CARBOCYCLIC RIBOTHYMIDINE FOR THE TREATMENT OF INFECTIONS AND CANCER
EP2133425A1 (en) * 2008-06-13 2009-12-16 Karin Mölling Method and compound for antiviral (HIV) therapy
US8541569B2 (en) * 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
EP4089169A1 (en) * 2009-10-12 2022-11-16 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
CA2859581C (en) 2011-12-16 2022-03-22 National University Corporation Tokyo Medical And Dental University Chimeric double-stranded nucleic acid

Also Published As

Publication number Publication date
CA2859581C (en) 2022-03-22
US20210340540A1 (en) 2021-11-04
JP2021011501A (ja) 2021-02-04
JP7174384B2 (ja) 2022-11-17
CA2859581A1 (en) 2013-06-20
CN112386605A (zh) 2021-02-23
JP2017140031A (ja) 2017-08-17
ES2707232T3 (es) 2019-04-03
JP2022000426A (ja) 2022-01-04
US20180320181A1 (en) 2018-11-08
CA3106312A1 (en) 2013-06-20
US20140302603A1 (en) 2014-10-09
JP2018203779A (ja) 2018-12-27
JP2022171811A (ja) 2022-11-11
JP6112569B2 (ja) 2017-04-12
US9816089B2 (en) 2017-11-14
CN104126010A (zh) 2014-10-29
EP2791335B1 (en) 2018-11-14
JP6416301B2 (ja) 2018-10-31
AU2012353330A1 (en) 2014-07-31
CN104126010B (zh) 2021-04-06
EP2791335A1 (en) 2014-10-22
WO2013089283A1 (en) 2013-06-20
JP6960123B2 (ja) 2021-11-05
JP6638923B2 (ja) 2020-02-05
JP7423015B2 (ja) 2024-01-29
US11034955B2 (en) 2021-06-15
JP2015502134A (ja) 2015-01-22
US20180073024A1 (en) 2018-03-15
US20190270996A1 (en) 2019-09-05
US10329567B2 (en) 2019-06-25
AU2012353330B2 (en) 2018-04-19
US10337006B2 (en) 2019-07-02
JP2020039364A (ja) 2020-03-19

Similar Documents

Publication Publication Date Title
IN2014CN04590A (US06268490-20010731-C00004.png)
EP2580355A4 (en) A REVERSE TRANSCRIPTION AND THROUGH BASE-SPACING RESTRICTED QUANTITATIVE PCR PROVIDED THROUGH AN OLIGONUCLEOTIDE WITH A CHANGED HAIR NEEDLE STRUCTURE
IN2013MN00522A (US06268490-20010731-C00004.png)
EP4086347A3 (en) Selective antisense compounds and uses thereof
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
MX2021015290A (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
WO2010080129A3 (en) Extended dicer substrate agents and methods for the specific inhibition of gene expression
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
MX342195B (es) Nucleótidos de terminación de rápida fotodescomposición 5-metoxi, 3' -oh no bloqueados y métodos para secuenciación de ácido nucleico.
WO2011123621A3 (en) 2' and 5' modified monomers and oligonucleotides
WO2012142611A3 (en) Sequencing small amounts of complex nucleic acids
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
EP4269584A3 (en) Selective antisense compounds and uses thereof
NZ601247A (en) Targeted genomic alteration
JP2012050447A5 (US06268490-20010731-C00004.png)
SG10201804076RA (en) Methods for multiplex detection of alleles associated with ophthalmic conditions
WO2012046085A3 (en) Methods of inducing insulin production
WO2012168307A3 (en) Improved recombination efficiency by inhibition of nhej dna repair
WO2013010062A3 (en) Nucleic acid complexity reduction
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
WO2012078967A3 (en) Compositions and methods for increasing erythropoietin (epo) production
WO2012178033A3 (en) Serpina1 sirnas: compositions of matter and methods of treatment
WO2007147067A8 (en) Methods and compositions for regulating cell cycle progression
Kaur et al. Reduction in carotenoid levels in the marine diatom Phaeodactylum tricornutum by artificial microRNAs targeted against the endogenous phytoene synthase gene
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes